143 related articles for article (PubMed ID: 21950458)
1. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Yasui-Furukori N; Kojima M; Uno T
Br J Clin Pharmacol; 2012 Mar; 73(3):478-81. PubMed ID: 21950458
[TBL] [Abstract][Full Text] [Related]
2. Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers.
Akamine Y; Miura M; Yasui-Furukori N; Ieiri I; Uno T
J Clin Pharm Ther; 2015 Feb; 40(1):98-103. PubMed ID: 25263393
[TBL] [Abstract][Full Text] [Related]
3. An update on the clinical pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):429-434. PubMed ID: 29635947
[TBL] [Abstract][Full Text] [Related]
4. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.
Tateishi T; Miura M; Suzuki T; Uno T
Br J Clin Pharmacol; 2008 May; 65(5):693-700. PubMed ID: 18294330
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.
Sakugawa T; Miura M; Hokama N; Suzuki T; Tateishi T; Uno T
Br J Clin Pharmacol; 2009 May; 67(5):535-40. PubMed ID: 19552748
[TBL] [Abstract][Full Text] [Related]
6. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T
Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
[TBL] [Abstract][Full Text] [Related]
7. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Sunagawa S; Kagaya H; Yasui-Furukori N; Uno T
Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
[TBL] [Abstract][Full Text] [Related]
8. The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion.
Akamine Y; Miura M; Komori H; Tamai I; Ieiri I; Yasui-Furukori N; Uno T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):352-7. PubMed ID: 26213156
[TBL] [Abstract][Full Text] [Related]
9. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
Kim KA; Park PW; Park JY
Eur J Clin Pharmacol; 2009 Jun; 65(6):609-14. PubMed ID: 19221726
[TBL] [Abstract][Full Text] [Related]
10. Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Komori H; Saito S; Kusuhara H; Tamai I; Ieiri I; Uno T; Yasui-Furukori N
Eur J Clin Pharmacol; 2014 Sep; 70(9):1087-95. PubMed ID: 24903351
[TBL] [Abstract][Full Text] [Related]
11. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.
Kim KA; Park JY
Eur J Clin Pharmacol; 2010 Jul; 66(7):721-5. PubMed ID: 20306185
[TBL] [Abstract][Full Text] [Related]
12. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.
Saruwatari J; Yasui-Furukori N; Niioka T; Akamine Y; Takashima A; Kaneko S; Uno T
J Clin Psychopharmacol; 2012 Apr; 32(2):195-9. PubMed ID: 22367658
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Calvo E; Lee JS; Kim SW; Moreno V; deCastro Carpeno J; Weilert D; Laus G; Mann H; Vishwanathan K
J Clin Pharmacol; 2019 Aug; 59(8):1099-1109. PubMed ID: 30875094
[TBL] [Abstract][Full Text] [Related]
14. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study.
Pinto LSR; Vale GTD; Moreira FL; Marques MP; Coelho EB; Cavalli RC; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1145():122094. PubMed ID: 32311673
[TBL] [Abstract][Full Text] [Related]
15. Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model.
Pinto L; Bapat P; de Lima Moreira F; Lubetsky A; de Carvalho Cavalli R; Berger H; Lanchote VL; Koren G
Pharm Res; 2021 Apr; 38(4):647-655. PubMed ID: 33825113
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fexofenadine enantiomers in healthy subjects.
Miura M; Uno T; Tateishi T; Suzuki T
Chirality; 2007 Mar; 19(3):223-7. PubMed ID: 17230498
[TBL] [Abstract][Full Text] [Related]
17. Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics.
Pinto L; Moreira FL; Nardotto GHB; Cavalli RC; Moisés ECD; Duarte G; Lanchote VL
Pharm Res; 2020 Jun; 37(7):131. PubMed ID: 32557079
[TBL] [Abstract][Full Text] [Related]
18. [Determinants of the stereoselective pharmacokinetics of fexofenadine].
Akamine Y
Yakugaku Zasshi; 2015; 135(3):473-81. PubMed ID: 25759055
[TBL] [Abstract][Full Text] [Related]
19. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
Shimizu M; Uno T; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
